Current clinical evidence suggests that starting GLP-1 therapy in gastroparesis requires careful medical evaluation and baseline gastric function assessment, not automatic exclusion from treatment
If you reside in Phoenix, Scottsdale, or Glendale and are looking for a potent way to enhance your overall health and well-being, this therapy might be your ideal solution
Check Your Eligibility Free Consultation (Prospective Patients) Starting July 1, 2026 , Medicare Part D covers Wegovy, Zepbound, and Foundayo for weight loss through the new GLP-1 Bridge program
There was a significant decrease in weight with those taking combination therapy versus placebo (monotherapy)
Bacteriostatic water and mixing syringe provided
Drugs such as Wegovy (semaglutide) and Saxenda (liraglutide) fall into this category of receptor agonists and are often given by subcutaneous injection due to their limited oral bioavailability